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ABSTRACT
Objectives: Exosomes — microvesicles which are secreted by living cells — can be produced from different cell types and 
detected in various body fluids. They are the carriers of intercellular information which regulate tumor microenvironment 
and are considered to be involved in tumor progression and metastasis. Cancer cells can secrete more exosomes than healthy 
cells, and are expected to be potential tools for tumor diagnosis and treatment. 
Material and methods: In this report, we present the results of microparticle analysis in peripheral and uterine blood of 
patients with endometrial cancer. To the best of our knowledge, this study has been the first to report microvesicle status 
in peripheral and uterine blood samples. The aim of the study was to determine the amount of total (TF+), endothelial 
(CD144+) and monocytic (CD14+) microparticles. The counting of the selected microparticles in citrate plasma was per-
formed using flow cytometry on the BD Canto II cytometer. 
Results: We found that the total amount of microparticles in cancer patients was much higher than in healthy controls. More-
over, microparticle count in uterine blood was higher than in peripheral blood of patients with endometrial cancer. We 
also demonstrated that the amount of microparticles correlates with the histologic grade and clinical stage of the tumor.
Conclusions: The most interesting finding in this work was the high level of  TF, CD144  and CD14  MPs in uterine blood 
samples. Thus we can consider the monocyte-macrophage-derived MPs as a candidate marker of endometrial cancer and 
maybe very critical part of the endometrial carcinogenesis. 
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INTRODUCTION
Malignant tumors are one of the main factors contrib-
uting to high morbidity and mortality rates around the 
world [1, 2]. Over the next decades, a further increase in 
tumor-related mortality is expected. The steadily increasing 
morbidity and mortality rates result, among others, from the 
extending life expectancy.
Endometrial cancer (EC) is the most common malignant 
tumor of the female reproductive system in the developed 
countries. According to the latest data from the National 
Register of Tumors, out of 6243 women diagnosed with EC 
in 2015 in Poland, 1690 died. In the vast majority of cases, 
EC develops after the menopause and it is diagnosed before 
the age of 40 only in 5% of the cases [3].
Old age, diabetes, hypertension and obesity are 
well-known risk factors for EC. Type I EC develops on the ba-
sis of irregular proliferation of the endometrium caused by 
hormonal stimulation. In contrast, type II EC is hormone-re-
sistant and develops from a thin, atrophic endometrium 
[4–6]. No screening method allows to detect pre-malignant 
683
Marek Dziechciowski et al., Diagnostic and prognostic relevance of microparticles in peripheral and uterine blood of patients with endometrial cancer
www. journals.viamedica.pl/ginekologia_polska
and intraepithelial lesions of the endometrium. Neither Pap 
smear nor transvaginal ultrasonography constitute suffi-
cient screening criteria. Therefore, the search for a specific 
biochemical marker, which could be useful in endometrial 
cancer screening, continues [5–7]. One of the most prom-
ising areas of research in modern oncology is the search 
for biomarkers enabling and facilitating early diagnosis, 
prognosis and monitoring of cancer treatment.
It has been well-established that cancer progression is 
largely dependent on abnormal angiogenesis, whereby new 
vessel formation ensures an adequate supply of nutrients, 
oxygen, and growth factors to the developing tumor and also 
facilitates tumor dissemination [8–10]. The results of loss of 
endothelial cell integrity, dysfunction of the endothelium and 
prolonged or unregulated activation of the endothelial cells 
can be observed by the use of specific plasma markers [8–10].
The measurement of the circulating endothelial cells 
(CEC) level was proposed as a novel marker which could 
be used to assess vascular function, damaged in cancer-
ous conditions. More recently, endothelial microparticles 
have been proposed as novel and perhaps more attractive 
markers which are associated with vascular dysfunction in 
cancer. These endothelial microparticles (EMP) are vesicles 
formed by the endothelial cell membrane as a consequence 
of injury or activation. They are able to harbor cell surface 
proteins and cytoplasmic elements, thus expressing en-
dothelial specific surface markers which reflect the parent 
cell status [11, 12]. 
Microparticles (MPs) are a part of a general category of 
extracellular vesicles defined as microvesicles (MVs), which 
includes a population of membrane vesicles. MPs are het-
erogeneous in shape, ranging in size from 0.1 to 1 um. MPs 
are composed of fragments of the parent cell, which com-
prise the plasma membrane proteins and cytoplasmic and 
nucleic constituents of the parent cell [11, 12, 13]. MPs are 
released into the systemic circulation, where they can ef-
fectively deliver their cargo with a long range to recipient 
cells. Thus, they serve as systemic vehicles in mediating 
intercellular communication. MPs have been found to carry 
various bioactive molecules, proteins and nucleic acids, 
including mRNA and microRNA [14, 15]. Therefore, they 
must be involved in multiple aspects of cancer progression, 
angiogenesis, cellular survival and evasion of the immune 
surveillance. The presence of circulating endothelial micro-
particles has recently been recognized as a useful marker of 
vascular damage and may have a potentially significant role 
to play in the evaluation of tumor angiogenesis and tumor 
growth [8, 16]. Usually absent in the blood of healthy indi-
viduals, MPs counts are elevated in diseases hallmarked by 
the presence of vascular insult, such as neoplastic process-
es. Circulating endothelial cells are supposed to be the con-
sequence of a particular pathology such as cancer [13, 17]. 
Researches have demonstrated the key role of MPs in the 
growth, division, and maturation of endothelial precursor 
cells, important for blood vessel regeneration [8, 9, 13, 17]. 
It has been confirmed that cancer cells secrete more MPs 
than healthy cells, but the contents of these MPs have been 
found to be very distinct from each other [13, 17]. Inter-
estingly, cancer cell-derived microparticles can provide 
a suitable microenvironment for cancer development and 
it would be most beneficial to gain a more detailed knowl-
edge about them.
Objectives
In the present work, we evaluated MPs levels in pa-
tients with endometrial cancer and in healthy controls. We 
hypothesized that MPs count is directly proportional to 
tumor development. Moreover, we compared MPs counts 
in peripheral and uterine blood as we expected that there 
must be an early marker in the uterine cavity which could 
be detected. We suspected that a higher level of MPs would 
be found in uterine blood samples. We also investigated the 
hypothesis that MPs counts could correlate with cancer cells 
grading (based on histologic grading system, G) and clinical 
stage (based on FIGO staging system). 
MATERIAL AND METHODS
The study was approved by the Jagiellonian University 
Medical College Ethic Committee. All individuals involved in the 
study gave their written informed consent. We included 37 pa-
tients, aged > 40–75, who were interviewed for their medical 
history and who had histologically proven endometrial cancer, 
to the endometrial cancer group. The control group consisted 
of healthy volunteers (23 women aged > 40–65 years).
Blood was collected on citrate, and centrifuged for 
15 min at 1500 x g at room temperature. The obtained 
plasma was briefly centrifuged again for 15 min at 1500 x g 
at room temperature and aliquoted into 1.5 mL tubes and 
frozen at -80°C until assayed.
Reagents
 The following reagents were used for the determina-
tion of the selected MPs: Antibodies against tissue factor 
with PE (phycoerythrin) (Biolegend, USA) APC (Allophyco-
cyanin) (Biolegend, USA) — marker of all microparticles, 
Monocyte differentiation antigen also known as CD14 with 
FITC (fluorescein) (Biolegend, USA) — marker of mono-
cyte microparticles, and vascular endothelial cadherin 
also known as CD144 with PE (phycoerythrin) (Biolegend, 
USA) — as a marker for endothelial microparticles. Appro-
priate isotype control was also used to set the method: 
mouse antibody IgG1- PE (Biolegend, USA), mouse antibody 
IgG1- APC (Biolegend, USA), mouse antibody IgM- Pacific 
Blue (Biolegend, USA). 
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The counting of the selected MPs in citrate 
plasma
 We applied the following procedure: 20 μL of plasma 
sample was added to 80 μL of cold PBS. 5 μL of Tissue fac-
tor — APC and 5 μL of the selected antibodies were added 
to each tube. They were then incubated for 20 min. in the 
dark at room temperature. After this time, 400 μL PBS buffer 
were added and measured at low flow for 1 min on a BD 
Canto II cytometer. 
Statistical analysis
Based on the manufacturer’s flow information (10 μL/sec) 
and the flow time and dilution of the sample, we know how 
many microparticles were in patient plasma. Regularity of 
distribution of the results was assessed using the Kolmogo-
rov-Smirnov test. Non-parametrically distributed results were 
presented as medians and inter-quartile differences, and me-
dians were compared using the ANOVA Range Kruskal Wallis 
and U-Mann Whitney test. The p-value of < 0.05 was considered 
as statistically significant. Spearman correlation coefficient was 
used to evaluate the correlation.
RESULTS 
The total amount of endogenous MPs was determined 
and characterized by flow cytometry using tissue factor TF. 
For identification of endothelial MPs, antibody against hu-
man CD144 was used, and for monocytes against CD14. At 
first, we measured the total amount of circulating MPs in 
peripheral blood in the control group as compared to EC 
patients. The total amount of TF+ MPs was much higher in 
the EC group than controls (3381 [2410–5925]; P < 0.001) 
(Tab. 1). The count of cells demonstrating positive CD144+ 
fluorescence which represented endothelial MPs was seven 
times higher in peripheral blood of EC patients. The same 
observation was made with regard to the amount of mono-
cytic MPs. Their count was higher in EC patients than healthy 
controls (402 [126–3188]; P < 0.0001).
Next, we analyzed the total amount (TF+), endothelial 
MPs (CD144+) and monocytic (CD14+) in peripheral and 
uterine blood of patients with EC (Tab. 2). We found that the 
total amount of circulating MPs was higher in uterine blood 
(7542 [3687–10745], P < 0.0027), whereas the level of en-
dothelial and monocytic MPs was reduced in uterine blood 
samples and only for MPs demonstrating positive CD14+ we 
observed the statistical significance with P < 0.0251. 
We also demonstrated a correlation between circulat-
ing MPs count and histologic grading (G). We distinguished 
3 groups of patients with endometrial cancer based on the 
histologic grading system G (G1/G2/G3). The results are 
shown in Table 3. MPs counts were different. The highest 
level of the total MPs was observed in group G3 in uterine 
blood (7779 [4687–9515]), whereas the values were lower 
Table 1. Flow cytometry results for total amount of circulating and 
endothelial MPs and monocytic MPs in peripheral blood of patients 
with endometrial cancer as compared to the control group
CONTROL 
GROUP, N = 23
ENDOMETRIAL 
CANCER, N = 37 
(peripheral blood)
P
TF+ 435 [345–592] 3381 [2410–5925] < 0.0001
TF+CD144+ 116 [80–142] 749  [476–1275] < 0.0001
TF+CD14+ 82  [57–95] 402  [126–3188] < 0.0001
Total amount of MPs is defined as TF+, whereas endothelial MPs are character-
ized by CD144+ and monocytic MPs by CD14+
Table 2. Flow cytometry results for total amount of circulating and 
endothelial MPs and monocytic in patients with endometrial cancer
ENDOMETRIAL 
CANCER, N = 37 
(peripheral blood)
ENDOMETRIAL 
CANCER, N = 37
(uterine blood)
P
TF+ 3381 [2410–5925] 7542 [3687–10745]  0.0027
TF+CD144+ 749  [476–1275] 484  [268–1154]  0.1652
TF+CD14+ 402  [126–3188] 252  [139–453]  0.0251
Total amount of MPs is defined as TF+, whereas endothelial MPs are character-
ized by CD144+ and monocytic by CD14+. Comparison of MPs level in peripheral 
blood and uterine blood samples from the same patients with endometrial 
cancer
Table 3. Flow cytometry results for total amount of circulating and endothelial MPs and monocytic in patients with endometrial cancer
G1, N = 15 G2, N = 13 G3, N = 9 P
TF+ 2714 [2343–6316] 3672 [2683–5080] 3533 [1681–15259] 0.8830
TF+CD144+ 731  [464–842] 1123 [636–1864] 582  [476–1290] 0.4927
TF+CD14+ 319  [224–543] 451  [252–556] 348  [294–628] 0.8627
U TF+ 7555 [2253–13496] 6484 [3687–10745] 7779 [4687–9515] 0.9163
U TF+CD144+ 613  [265–1494] 471  [273–1154] 484  [268–600] 0.6661
U TF+CD14+ 363  [129–577] 252  [155–412] 201  [134–283] 0.8587
Total amount of MPs is defined as TF+, whereas endothelial MPs are characterized by CD144+ and monocytic by CD14+. Comparison of MPs level based on histologic grad-
ing (G). (ANOVA Range Kruskal Wallis). U is defined for results in uterine blood samples
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for CD144+ and CD14+ MPs in uterine blood, especially in 
group G3. However, due to a very low number of samples 
(N = 15 for G1, N = 13 for G2 and only N = 9 for G3), no 
statistically significant trends were observed for this step 
of the performed analysis.
In Table 4, we presented two-fold higher numbers of the 
total MPs in uterine blood for FIGO I stage of endometrial 
cancer in comparison to the MPs count in peripheral blood. 
The lower CD144+ and CD14+ MPs count was observed in 
uterine blood samples both, for FIGO I and FIGO > III stage 
of endometrial cancer. We were not able to confirm these 
results statistically due to the low and not equal number of 
samples from FIGO I and FIGO > III groups. 
In Table 5, Spearman correlation coefficients between 
MPs count (total, endothelial and monocytic) are shown. 
We found significant correlations for the total MPs count 
(TF+) and the endothelial (TF+CD144+) and monocytic 
(TF+CD14+) MPs. Moreover, we found correlations between 
endothelial and monocytic MPs both, in peripheral and 
uterine blood of patients with endometrial cancer. 
DISCUSSION
Endothelial homeostasis is crucial in many pathological 
conditions, including vascular damage, regeneration and 
adult neovasculogenesis. In many recent studies, it has been 
demonstrated that MPs may reflect the endothelium status 
in both, health and disease [10, 13, 17]. In human blood, cir-
culating endothelial MPs have been widely associated with 
endothelial dysfunction, suggesting a potential preservative 
role in response to vascular regeneration, restoration, and 
protection. It is important to identify differences in the level 
of MPs in healthy and pathological conditions. Clinical appli-
cations of membrane vesicles are still in the developmental 
stage and their full potential is yet to be explored. Despite nu-
merous studies on the role of MPs in cancer pathogenesis, the 
number of reports on their role in endometrial cancer remains 
limited. High levels of MPs in cancer have been reported but 
in many cases those levels fail to be associated with progres-
sion and staging [13, 17]. Newly demonstrated ways of as-
sessing vascular function in the treatment of cancer include 
the measurement of levels of CEC and circulating endothelial 
microparticles. An increased MPs count in peripheral blood 
reflects significant vascular damage and dysfunction. Re-
cently, an interest in the evaluation of the endothelial-specific 
adhesion molecule VE-cadherin (cadherin-5 or CD144), spe-
cifically in the context of tumor angiogenesis, has increased 
[8, 9]. It has been proven that monocytic molecules activate 
endothelial cells. In addition, it has been demonstrated that 
there are very close correlations between endothelium-de-
rived and monocytic-derived microparticles. In our study, we 
found higher levels of the total and endothelial MPs as well as 
monocytic in the peripheral blood samples from the patients 
Table 4. Flow cytometry results for total amount of circulating and endothelial MPs and monocytic in patients with endometrial cancer
FIGO I, N = 27 FIGO > III, N = 9 P
TF+ 3180 [2343–5925] 3533 [2683–3968] 0.970857
TF+CD144+ 731  [464–986] 1190 [520–1290] 0.323941
TF+CD14+ 348  [252–543] 531  [219–628] 0.583695
U TF+ 7555 [4498–12208] 6484 [3206–10745] 0.714865
U TF+CD144+ 525  [296–1236] 363  [173–994] 0.235100
U TF+CD14+ 258  [147–543] 167  [129–453] 0.411080
Total amount of MPs is defined as TF+, whereas endothelial MPs are characterized by CD144+ and monocytic by CD14+. Comparison of MPs level based on clinical status 
of endometrial cancer (based on FIGO-grade) (U Mann Whitney). U is defined for results in uterine blood samples
Table 5. Flow cytometry results for the correlations between total amount of circulating and endothelial MPs and monocytic in patients with 
endometrial cancer
Variables TF+ TF+CD144+ TF+CD14+ U TF+ UT F+CD144+ U TF+CD14+
TF+ 1.000000 0.833194 0.820309 0.397108 0.363108 0.363108
TF+CD144+ 0.833194 1.000000 0.947502 -0.163348 0.124948 0.124948
TF+CD14+ 0.820309 0.947502 1.000000 0.022645 0.230792 0.230792
U TF+ 0.397108 -0.163348 0.022645 1.000000 0.650821 0.650821
U TF+CD144+ 0.363108 0.124948 0.230792 0.650821 1.000000 1.000000
U TF+CD14+ 0.342640 0.105045 0.191628 0.674017 0.917062 0.917062
Total amount of MPs is defined as TF+, endothelial MPs are characterized by CD144+ and monocytic by CD14+. Correlations between MPs were evaluated using Spear-
man correlation coefficients (r = 0.78, 0.87, and 0.90, respectively; all P < 0.05000). U is defined for results in uterine blood samples
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with endometrial cancer. Our findings are in accordance with 
other studies performed to date. The levels of TF+, CD144+ 
and CD14+ MPs in uterine blood samples are a particularly 
interesting and innovative finding of our study. To the best 
of our knowledge, this has been the first report concern-
ing MPs in the uterine blood of patients with endometrial 
cancer. We demonstrated that the total TF+ MPs count was 
higher in uterine blood in comparison to peripheral blood. 
The quantity of endothelial and monocytic MPs was lower but 
two-fold higher numbers for CD144+ positive microparticles 
in comparison with CD14+ were found.
We were slightly surprised to find that the levels of MPs 
were neither related to the clinical stage (FIGO) nor to the 
histologic grading (based on G) of the tumor. We suppose 
that the reason for that could be lack of statistical power due 
to a relatively small sample size in our study, although it may 
also reflect pathophysiological processes. The highest level 
of total MPs in uterine blood as compared to the peripheral 
blood samples as well as to the healthy group suggested that 
there must be some unspecific cells which we were not able 
to identify using CD144 and CD14 markers, or that there are 
some unknown pathophysiological changes underlying this 
type of cancer. In human blood, endothelial MPs constitute 
a smaller population of MPs family. However, they are associ-
ated with the pathogenesis of various cardiovascular diseases, 
mainly initiated by endothelial dysfunction [8]. In our study, we 
found that monocytic MPs (CD14+) may increase endothelial 
MPs (CD144+) count, and what is very interesting, that there 
were many correlations between monocytic and endothelial 
MPs, which may indicate their similar functions in pathologi-
cal conditions. What is more, the analysis of endothelial and 
monocytic MPs in correlation with the histologic grading and 
clinical stage of endometrial cancer yielded higher levels of 
CD144+ and CD14+ particles in G1 and FIGO I in comparison 
to G3 and FIGO > III. These results may indicate that in a his-
tologically advanced and late clinical stage of cancer there 
is a higher accumulation of dead cells. However, it can also 
mean that MPs could serve as a marker for early detection of 
endometrial cancer, but further studies are needed.
In the future studies, we should focus more on the samples 
from the uterine cavity as an organ where markers may appear 
earlier than in the peripheral blood. We suggest that micropar-
ticles in the uterine blood should be characterized in detail. 
Particularly, we should be more focused on their involvement 
in molecular processes in which cancer-related MPs could be 
involved. We are aware that there are several limitations of this 
study. Despite our best efforts to minimize the confounding 
factors by careful screening of the patients and controls, it is 
possible that some factors have not been adequately verified. 
However, our data suggest that MPs may be considered as a can-
didate biomarker for early detection of endometrial cancer. 
It seems prudent to perform additional studies, concentrating 
on the uterine cavity where the endometrial cancer prolif-
eration starts. Endothelial MPs release is triggered by various 
stimuli followed by the activation of various pathways which 
can be involved in carcinogenesis. As we know, many factors 
such as oxidative stress, endogenous molecules and apoptosis 
inducer are responsible for endothelial MPs release to undergo 
a functional change in the blood vessel. The monocyte-mac-
rophage-derived MPs may also play a role in the progression 
of endometrial cancer. It is worth noting that medicines tar-
geting the downregulation of endothelial, monocytic or other 
MPs release can be a possible therapeutic option for treating 
endometrial or other gynecological tumors.
CONCLUSIONS
Endothelial microparticles release is triggered by various 
stimuli, followed by the activation of various pathways which 
can collectively make progress in the endometrial cancer 
advancement. Moreover, monocyte-macrophage-derived 
MPs may also be a very critical part of the endometrial 
carcinogenesis. According to our data, the total amount 
of microparticles in cancer patients is much higher than in 
healthy subjects. In uterine blood, the count of micropar-
ticles is higher than in peripheral blood of patients with 
endometrial cancer. MPs count in uterine blood can be 
considered as a candidate marker of endometrial cancer 
and detailed evaluation of MPs continues to present a big 
challenge, especially to discover their clinical utility. 
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